G1 Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- G1 Therapeutics's estimated annual revenue is currently $42.2M per year.
- G1 Therapeutics received $47.0M in venture funding in May 2016.
- G1 Therapeutics's estimated revenue per employee is $354,874
- G1 Therapeutics's total funding is $497.3M.
- G1 Therapeutics's current valuation is $429.9M. (January 2022)
Employee Data
- G1 Therapeutics has 119 Employees.
- G1 Therapeutics grew their employee count by -37% last year.
G1 Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Communications Officer; VP, Investor Relations & Corporate Communications. Executive Team member. | Reveal Email/Phone |
3 | COO | Led Team to Drive Enrollment for Global Phase III Clinical Trial | Reveal Email/Phone |
4 | Head Talent Acquisition | Reveal Email/Phone |
5 | Controller | Reveal Email/Phone |
6 | VP Information Technology | Reveal Email/Phone |
7 | SVP, Technical Operations | Reveal Email/Phone |
8 | VP, Regulatory Affairs | Reveal Email/Phone |
9 | VP, Head Biometrics | Reveal Email/Phone |
10 | SVP Clinical Operations | Reveal Email/Phone |
G1 Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $11.2M | 72 | -13% | N/A | N/A |
#2 | $5099.8M | 32902 | -4% | N/A | N/A |
#3 | $1.7M | 11 | 0% | N/A | N/A |
#4 | $0.6M | 4 | -56% | N/A | N/A |
#5 | $0.9M | 11 | -39% | N/A | N/A |
#6 | $1.7M | 11 | 10% | N/A | N/A |
#7 | $0.6M | 4 | -33% | N/A | N/A |
#8 | $4.8M | 31 | -6% | N/A | N/A |
#9 | $6.4M | 41 | 3% | N/A | N/A |
#10 | $4.2M | 27 | -18% | N/A | N/A |
What Is G1 Therapeutics?
G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of cancer. Two of the company's pipeline assets, trilaciclib and G1T38, are CDK4/6 inhibitors, a validated and promising class of oncology therapeutics. Trilaciclib and G1T38 have broad therapeutic potential in many forms of cancer and may serve as backbone therapy of multiple combination regimens. Trilaciclib is a short-acting IV CDK4/6 inhibitor designed to preserve hematopoietic stem cell and immune system function (myelopreservation) during chemotherapy. G1T38 is a potential best-in-class oral CDK4/6 inhibitor for use in combination with other targeted therapies. G1 is also advancing G1T48, a potential best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of ER+ breast cancer. G1 is based in Research Triangle Park, NC. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$497.3M
Total Funding
119
Number of Employees
$42.2M
Revenue (est)
-37%
Employee Growth %
$429.9M
Valuation
N/A
Accelerator
G1 Therapeutics News
G1 Therapeutics posted earnings of ($0.65) per share during the same quarter last year, which indicates a negative year over year growth rate of...
Equities research analysts expect that G1 Therapeutics, Inc. (NASDAQ:GTHX - Get Rating) will post earnings per share of ($0.99) for the...
Since my last five articles on G1 Therapeutics (NASDAQ:GTHX) over the last 24 months, the stock is down 84%, 58%, 72%, 59% and 56%...
G1 Therapeutics Provides Third Quarter 2021 Financial Results and Operational Highlights - Achieved $4.9 Million in Total Revenue, Including $3.6 Million in Net Revenue from Sales of COSELA™ (trilaciclib) - - Announced Supplemental COSELA Sales Force to Target Top Tier Accounts and Publication ...
RESEARCH TRIANGLE PARK, North Carolina, Oct. 01, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the permanent J-code for COSELA™ (trilaciclib) that was issued in July 2021 by the Centers for Medicare & Medicaid Services (C ...
Other Companies in Research Triangle Park
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $20.3M | 131 | 30% | N/A |
#2 | $7.5M | 217 | 32% | N/A |
#3 | $83.2M | 414 | 7% | N/A |
#4 | $114.6M | 528 | 60% | $241.8M |
#5 | $566.7M | 2926 | 20% | N/A |
G1 Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2013-10-17 | $12.5M | A | MedImmune Ventures | Article |
| 2015-02-06 | $33.0M | B | Multiple | Article |
| 2016-05-13 | $47.0M | C | Cormorant Asset Management | Article |